Nilotinib dihydrochloride dihydrate is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.
Nilotinib hydrochloride dihydrate is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.
Nilotinib-D6 is a deuterium labeled Nilotinib (T1524) which is an orally available inhibitor of Bcr-Abl tyrosine kinase ,and with antineoplastic activity.